Global Dermatology Partnering 2016-2023: Deal Trends, Players and Financials

DUBLIN, April 7, 2023 /PRNewswire/ — The “Global Dermatology Partnering 2016-2023: Deal trends, players and financials” report has been added to  ResearchAndMarkets.com’s offering.

The Global Dermatology Partnering 2016-2023: Deal trends, players and financials report provides an understanding and access to the dermatology partnering deals and agreements entered into by the worlds leading healthcare companies.

• Trends in dermatology partnering deals
• Financial deal terms for headline, upfront and royalty by stage of development
• Dermatology partnering agreement structure
• Dermatology partnering contract documents
• Top dermatology deals by value
• Most active dermatology dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive dermatology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering dermatology deals.

The report presents financial deal terms values for dermatology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of dermatology dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in dermatology dealmaking since 2016 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading dermatology deals since 2016. Deals are listed by headline value. The chapter includes the top 25 most active dermatology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to dermatology deals since 2016 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all dermatology partnering deals by specific dermatology target announced since 2016. The chapter is organized by specific dermatology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all dermatology partnering deals signed and announced since 2016. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in dermatology partnering and dealmaking since 2016.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of dermatology technologies and products.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Report scope

Global Dermatology Partnering 2016-2023 is intended to provide the reader with an in-depth understanding and access to dermatology trends and structure of deals entered into by leading companies worldwide.

Global Dermatology Partnering 2016-2023 includes:

• Trends in dermatology dealmaking in the biopharma industry since 2016
• Access to headline, upfront, milestone and royalty data
• Access to over 700 dermatology deal records
• The leading dermatology deals by value since 2016

The report includes deals for the following indications: Acne, Actinic keratosis, Angioedema, Burns, Cellulitis, Cosmetics, Dermatitis, Diabetic foot ulcer, Eczema, Hair disorders, Alopecia, Impetigo, Itching, Nail disorders, Psoriasis, Rosacea, Scabies, Sun damage, Rash, Scar, Venous ulcer, Verruca, Wound healing, Wrinkles, plus other dermatology indications.

In Global Dermatology Partnering 2016-2023, the available deals are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Dermatology Partnering 2016-2023 report provides comprehensive access to available deals and contract documents for over 700 dermatology deals.

Analyzing actual contract agreements allows assessment of the following:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are the sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Selection of Companies Mentioned

• 3D Systems
• 3M Critical & Chronic Care Solutions
• 23andMe
• Abbvie
• Accelis Pharma
• AccuTec Blades
• Acelity
• Acell
• Aclaris Therapeutics
• Actelion
• ADB International Group
• Adhesys Medical
• Advanced BioScience Laboratories
• Advanced Medical Solutions
• Advanced Plasma Products
• Advanz Pharma
• Aesthetic Management Partners
• Afinity Life Sciences
• Aghraas-Cigalah
• Air Force Research Laboratory
• AiVita Biomedical
• Akaal Pharma
• Alat Medika Indonesia
• Alibaba Health
• ALK-Abello
• Allergan
• Allergan (name changed from Actavis)
• Alliance Pharma
• Alliqua Biomedical
• AlloSource
• Almirall
• Alpha Pharma
• Alvotech
• Amarantus BioSciences
• American Academy of Professional Coders
• American Red Cross
• American Skin Association
• Amgen
• AMI
• AMNIOX
• Amor (Suzhou) Medical Sci-Tech
• AMSilk
• Amyris
• ANANDA Scientific
• Andrew Technologies
• Angelini Pharma
• AnGes MG
• Angionetics
• Anika Therapeutics
• ANI Pharmaceuticals
• Anteis
• Anterios
• Antibe Therapeutics
• AOTI
• APL
• Applied Biology
• APR Applied Pharma Research
• Apria Healthcare Group
• Aqua Pharmaceuticals
• Aralez Pharmaceuticals
• Aratana Therapeutics
• Arcutis Biotherapeutics
• arGEN-X
• Arrevus
• Arrien Pharmaceuticals
• Arsenal Medical
• Arthrex
• Art of Technology
• Aslan Pharma
• Astellas Pharma
• Astion Pharma
• AstraZeneca
• ATG Allied Technologies
• Athenex
• Atopix
• Aucta Pharmaceuticals
• Austen BioInnovation Institute in Akron (ABIA)
• Auven Therapeutics
• Avalon Pharmaceuticals
• Avaria Health & Beauty
• Avita Medical
• AvKARE
• Axcelon Dermacare
• Axonlab
• Axxess Pharma
• Azitra
• Back-A-Line
• BASF
• Basilea Pharmaceutica
• Bassett Salon Solutions
• Bausch & Lomb
• Bavarian Ministry for Economic Affairs and Media
• Energy and Technology
• Bayer
• Baylor Research Institute
• B Braun
• Beiersdorf
• Bellus Health
• Ben-Gurion University
• Berkshire Sterile Manufacturing
• Berlin-Brandenburg Center for Regenerative Therapies
• Berlin Chemie
• Best Choice
• BexPharm
• BGN Technologies
• Bill and Melinda Gates Foundation
• BioCad Holding
• Biocon
• BioCryst Pharmaceuticals
• BioDerm
• BioDlogics
• Biogen
• BiolineRX
• Biomedical Advanced Research and Development Authority
• BIOMEDX Group
• BioMed X Innovation Center
• Biometrix
• Biomillenia
• Bioniz Therapeutics
• Bionpharma
• Biophage Pharma
• BioPharm Group International
• Bioskin
• Biosolution
• BirchBioMed
• Bloomage BioTechnology
• BMG Pharmaceuticals
• Boehringer Ingelheim
• Boragen
• Boston Pharmaceuticals
• Boston Topicals
• BoyaLife
• Bpifrance
• Brickell Biotech
• Brigham and Women’s Hospital
• Bright Future Pharmaceutical Lab
• BSN Medical
• Cadila Pharmaceuticals
• CALECIM Cosmeceuticals
• Caliber Imaging & Diagnostics
• Can-Fite BioPharma
• CANbridge Life Sciences
• Candela
• CannaSkin
• Cannassure Therapeutics
• CanniMed Therapeutics
• Cantel Medical (UK)
• Capital Laser and Skin Care
• Cara Therapeutics
• CARB-X
• Cardiome Pharma
• Carestream Health
• Case Western Reserve University
• Castle Creek Pharmaceuticals
• CDx Diagnostics
• Celgene
• CellMark Medical
• Cell Mogrify
• Certara
• CHAMPS Group Purchasing
• Charite-Universitatsmedizin
• Chelexa Biosciences
• Chemipal
• Chemstar
• Children’s Hospital Boston
• China-Israel Biological Technology
• Chong Kun Dang
• Chongqing Jingdong Pharmaceutical
• Chromogenex Technologies
• Chugai Pharmaceutical
• Cimtech
• Cincinnati Children’s Hospital Medical Center
• Cipher Pharmaceuticals
• Cipla
• Circadia
• CIVCO Radiotherapy
• CJ CheilJedang
• Clarify Medical
• Clinipace Worldwide
• CMS Medical
• Collagen Solutions LLC
• Collagen Solutions Plc
• Collplant
• Columbia University Medical Center
• ConBio (Shanghai)
• Contem 1G
• ConvaTec
• Cook Biotech
• Cooper-Vemedia
• Cosmotec
• Covaleo
• Covalon Technologies
• Crescita Therapeutics
• CROMA Pharma
• Cronos Group
• Crown Bioscience
• Crown Laboratories
• Cryolife
• Cumberland Pharmaceuticals
• CURE Pharmaceutical
• Curetis
• Cutanea Life Sciences
• Cutanogen
• Cytori Therapeutics
• CytoSorbents
• Dabur
• Dalhousie University
• Daniel Alain Life Science
• DASH Analytics
• Dasman Diabetes Institute
• Daxor
• Dechra Pharmaceuticals
• Denali Therapeutics
• Department of Defence
• Department of Defense
• Department of Veterans Affairs
• DermaConcepts
• Dermala
• Derma Sciences
• Dermata Therapeutics
• Dermavant Sciences
• Dermelix Biotherapeutics
• Dermira
• Dermpath Diagnostics
• DermSpectra
• DermTech
• Devonian Health Group
• Dinaco
• Dipexium Pharmaceuticals
• Diplomat
• Dr. Falk Pharma
• Dr. Reddy’s Laboratories
• Dr. U Devices
• Dr Bragi Company
• Dr Kerklaan Therapeutics
• DS Healthcare
• Ducere Pharma
• Dukal
• Dynasil
• E-QURE
• Eccrine Systems
• Eclipse Aesthetics
• Eirion Therapeutics
• Eisai
• eKare
• Elanix Biotechnologies
• Elektrofi
• Elev8 Brands
• Ember Therapeutics
• Emory University
• Emphysys
• EMS
• Enaltus
• Encore Dermatology
• Encore Medical
• Enteris Biopharma
• Envy Medical
• Enzymatica
• Epicore Biosystems
• EPI Health
• Equillium
• Espada Dermatology
• EspeRare Foundation
• Ethicon Endo-Surgery
• Eureka Eurostars
• Eurofins Scientific
• Eve & Co
• Evolva
• Ewopharma
• Excelra
• Exicure
• Expanscience
• Fagron
• Ferrer International
• Fidelta
• Fillmed
• First Horizon Pharmaceuticals
• Fission Labs LATAM
• Flowerkist
• Follicum AB
• Food and Drug Administration (FDA)
• FormaTK Systems
• Fougera Pharmaceuticals
• Fujifilm Kyowa Kirin Biologics
• Fuji Pharma
• G-treeBNT
• Galapagos
• Galderma
• Gebro Pharma
• Gecko Biomedical
• Geisel School of Medicine at Dartmouth
• Gene Biotherapeutics
• Genentech
• General Biologicals
• Genfa Medica
• GHD GesundHeits
• Givaudan
• GlaxoSmithKline
• GL Brands
• GlobalMed
• GPC Systems
• Grunenthal
• Grupo Ferrer
• GtreeBNT
• Guangzhou Xiangxue Pharmaceutical
• Guthy-Renker
• H2-Pharma
• Hairmore Group
• Hapten Sciences
• Harvard Medical School
• Hawkeye Therapeutics
• Helsinn Healthcare
• Hemostasis
• Heumann Pharma Generics
• Hill Dermaceuticals
• Histapharm
• Histocell
• Histogen
• HitGen
• Hope Medicine
• Hoth Therapeutics
• Huapont Pharma
• Hugel
• Iagnosis
• Icahn School of Medicine at Mount Sinai
• Ice + Jam
• Ichnos Sciences
• Ideal Medical Solutions
• IDEAYA Biosciences
• iFyber
• ImaBiotech
• Imbed Bio
• IME Medical Electrospinning
• IMIDomics
• Immune Pharmaceuticals
• Immunomic
• Induce Biologics
• Innate Biologics
• Innovate UK
• Innovation Skane
• Innovative Cellular Therapeutics
• Innovus Pharmaceuticals
• Inova Diagnostics
• Institute for In Vitro Sciences
• Intalere
• Integra LifeSciences
• Intermountain Healthcare
• Interpolymer/Zschimmer & Schwarz
• Intralytix
• ISDIN
• ISIS Innovation
• Isoprene Pharmaceuticals
• Israeli National Authority for Technological Innovation
• ITEM Medical Technologies
• Jackson Laboratory
• Janssen Biotech
• Janssen Pharmaceuticals
• Janssen Pharmaceutica NV
• Janssen Research & Development
• Japan Tobacco
• JCR Pharmaceuticals
• Jiangsu Hengrui Medicine
• Jiangsu QYuns Therapeutics
• Johnson & Johnson Consumer Companies
• Johnson & Johnson Innovation
• Juntendo University
• JW Pharmaceutical
• Kaken Pharmaceutical
• Kane Biotech
• Karo Pharma
• Karyopharm Therapeutics
• Kavo Kerr Group
• Keck School of Medicine of USC
• Kent Imaging
• Kerecis

For more information about this report visit https://www.researchandmarkets.com/r/chtdja

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.Media

Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets